The bladder cancer treatment market is set to boom from an estimated $177.1 million in 2015 to over $646.6 million in 2017, as the launch of three new therapies over the next two years revitalizes a largely stagnant arena, according to research and consulting firm GlobalData.

The company's latest report states that the growth, which will occur across the 6 Major Markets (6MM) of the US, France, Germany, Italy, Spain and the UK, will be primarily down to the introduction of Telesta Therapeutics' MCNA and Roche's atezolizumab in 2016 and Bristol-Myers Squibb's Opdivoin 2017.

Dr Cai Xuan, GlobalData's Analyst covering Oncology, says: "Atezolizumab is on track to launch in the bladder cancer therapeutics space towards the end of 2016, and is one of many pipeline immune checkpoint inhibitors. This class of drugs has ignited substantial enthusiasm in recent years, as it has already shown efficacy in other difficult-to-treat cancers, including metastatic melanoma and lung cancer.

"As atezoliuzumab will be the first therapy of its kind to launch in this market, it will have a significant advantage, explaining why sales of the drug are forecast to account for 43.7% of the treatment space by 2017."

GlobalData's report also states that despite the clear the potential that the bladder cancer treatment market presents, there are several barriers that may inhibit growth.